Granix Disease Interactions
There are 3 disease interactions with Granix (tbo-filgrastim).
CSF (applies to Granix) glomerulonephritis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis. Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production. Advise patients to report signs or symptoms of glomerulonephritis immediately. Monitoring of patients with renal dysfunction is recommended.
Tbo-filgrastim (applies to Granix) sickle cell disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Sickle Cell Anemia
Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products. Consider the potential risks and benefits prior to initiating therapy in these patients.
Tbo-filgrastim (applies to Granix) tumor growth
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Myelodysplastic Disease
Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.
Switch to professional interaction data
Granix drug interactions
There are 175 drug interactions with Granix (tbo-filgrastim).
Report options
More about Granix (tbo-filgrastim)
- Granix consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: colony stimulating factors
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Zarxio
Zarxio (filgrastim-sndz) is biosimilar product used to treat neutropenia associated with ...
Neulasta
Neulasta is used to stimulate neutrophil growth and reduce infection risk (manifested by febrile ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Neupogen
Neupogen (filgrastim) is used to treat neutropenia, a lack of certain white blood cells caused by ...
Nivestym
Nivestym is used for bone marrow transplantation, neutropenia, neutropenia associated with ...
Fulphila
Fulphila is used for febrile neutropenia, neutropenia associated with chemotherapy
Udenyca
Udenyca is used for febrile neutropenia, hematopoietic syndrome of acute radiation syndrome ...
Releuko
Releuko is used for bone marrow transplantation, neutropenia, neutropenia associated with chemotherapy
Nyvepria
Nyvepria is used for febrile neutropenia, neutropenia associated with chemotherapy
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.